Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $50
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $45 to $50.
Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $45 to $50.